FLUORESCENT PROBE AND APPLICATIONS THEREOF
20220390458 · 2022-12-08
Assignee
- Centre National De La Recherche Scientifique (Cnrs) (Paris, FR)
- Universite Claude Bernard Lyon 1 (Villeurbanne, FR)
- INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (Paris, FR)
- INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (Villeurbanne, FR)
- CPE LYON FORMATION CONTINUE ET RECHERCHE pouvant être précédée ou suivie par CPE LYON FCR (VILLEURBANNE, FR)
- CENTRE LEON BERARD (LYON, FR)
- HOSPICES CIVILS DE LYON (LYON, FR)
Inventors
- Thierry GRANJON (LA TOUR DU PIN, FR)
- Ofelia MANITI (LA TOUR DU PIN, FR)
- Olivier MARCILLAT (LYON, FR)
- Peter GOEKJIAN (VILLEURBANNE, FR)
- Mouhedine CHENIOUR (SATHONAY CAMP, FR)
- Arnaud VIGNERON (ECLOSE-BADINIÈRES, FR)
- David GUEYRARD (VILLENEUVE, FR)
- Sébastien IBANEZ (CORBAS, FR)
Cpc classification
G01N21/6428
PHYSICS
G01N33/57492
PHYSICS
International classification
Abstract
##STR00001##
The invention relates a fluorescent compound of formula I: wherein A is selected from P, P═O and N; .Math.R.sup.1 is a residue comprising an oxygen atom.Math.R.sup.2 is a residue comprising an oxygen atom, or a halogen, .Math.R.sup.3, R.sup.4 and R.sup.5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.
Claims
1. Fluorescent compound of formula I: ##STR00024## wherein A is selected from P, P═O and N; R.sup.1 is selected from the group comprising hydrogen atom, NO.sub.2, NR.sup.6.sub.2, CH.sub.3, OR.sup.6, SO.sub.3H; Cl, F, CO.sub.2H, CONR.sup.6.sub.2, O.sub.2CR.sup.6, NHCOR.sup.6; NHCO.sub.2R.sup.6 and NHCONR.sup.6.sub.2 R.sup.2 is selected from the group comprising hydrogen atom, NO.sub.2, NH.sub.2, CH.sub.3, OH, SO.sub.3H and halogen; R.sup.3 is a C3-C25 alkyl, linear or branched, saturated or not, cyclic or not; R.sup.4 and R.sup.5 are selected from the group consisting of: R.sup.4 and R.sup.5 are either together and independently from each other a C2-C6 alkyl, linear or branched, saturated or not, cyclic or not, substituted by at least a hydroxyl group, R.sup.4 is a C3-C6 alkyl linear or branched, saturated or not, cyclic or not, substituted by at least two hydroxyl groups and R.sup.5 is a C1-C6 alkyl linear or branched, saturated or not, cyclic or not, not substituted, and R.sup.5 is a C3-C6 alkyl linear or branched, saturated or not, cyclic or not, substituted by at least two hydroxyl groups and R.sup.4 is a C1-C6 alkyl linear or branched, saturated or not, cyclic or not, not substituted; and R.sup.6 is selected in the group comprising hydrogen atom and a C1-C6 alkyl, linear or branched, saturated or not, cyclic or not, or a salt or a solvate thereof, preferably said fluorescent compound being of formula I-a: ##STR00025## wherein R.sup.3, R.sup.4 and R.sup.5 are as defined above.
2. The fluorescent compound according to claim 1 wherein said fluorescent compound is of formula I-a: ##STR00026## wherein: A is N; R.sup.3 is as recited in claim 1; R.sup.4 and R.sup.5 are selected from the group consisting of: R.sup.4 and R.sup.5 are either together and independently from each other a C2-C6 alkyl linear saturated, substituted by at least a hydroxyl group, R.sup.4 is a saturated C3-C6 alkyl, linear or branched, substituted by at least two hydroxyl groups and R.sup.5 is a C1-C6 alkyl, linear or branched, saturated, not substituted, and R.sup.5 is a C3-C6 alkyl, linear or branched, saturated substituted by at least two hydroxyl groups and R.sup.4 is a C1-C6 alkyl, linear or branched, saturated, not substituted.
3. The fluorescent compound according to claim 1, wherein R.sup.4 and R.sup.5 are together and independently from each other ##STR00027## or R.sup.4 is ##STR00028## and R.sup.5 is ##STR00029## or R.sup.4 is ##STR00030## and R.sup.5 is ##STR00031## wherein n and m are together and independently from each other an integer from 1 to 4, and wherein the sum of n and m is an integer from 2 to 5.
4. The fluorescent compound according to claim 1 of the following formula: ##STR00032##
5. Method for in vitro and ex vivo labelling a lipid membrane or part thereof comprising a step of contacting a fluorescent compound according to claim 1 with a lipid membrane or part thereof, and a step of detecting the fluorescence of the said lipid membrane or part thereof labelled by the said fluorescent compound.
6. The method for in vitro and ex vivo labelling a lipid membrane according to claim 5, wherein the lipid membrane or part thereof is selected from a lipid monolayer membrane and a lipid bilayer membrane.
7. The method in vitro and ex vivo for labelling a lipid membrane according to claim 5, wherein the lipid membrane is a eukaryote cell lipid membrane.
8. (canceled)
9. Method for in vitro and ex vivo evaluating the degree of fluidity of a lipid membrane, said method comprising the steps of: a) labelling a lipid membrane or part thereof with a fluorescent compound according to claim 1 by a method comprising a step of contacting a fluorescent compound according to claim 1 with a lipid membrane or part thereof, and a step of detecting the fluorescence of said lipid membrane or part thereof labelled by the said fluorescent compound, b) determining a generalized polarization parameter GP of the lipid membrane or part thereof by the following formula
10. Method for in vitro and ex vivo evaluating the degree of fluidity of a lipid membrane, said method comprising the steps of: a) labelling a lipid membrane or part thereof with a fluorescent compound according to claim 1 by a method comprising a step of contacting a fluorescent compound according to claim 1 with a lipid membrane or part thereof, and a step of detecting the fluorescence of said lipid membrane or part thereof labelled by the said fluorescent compound, b) determining a generalized polarization parameter GP of the lipid membrane or part thereof by the following formula
11-12. (canceled)
13. Method for the in vitro and ex vivo diagnosis of a cancer in an individual, said method comprising the steps of: a) labelling a cell membrane or part thereof in a sample of an individual with a fluorescent compound according to claim 1 by a method comprising a step of contacting a fluorescent compound according to claim 1 with a lipid membrane or part thereof, and a step of detecting the fluorescence of said lipid membrane or part thereof labelled by the said fluorescent compound, b) determining a generalized polarization parameter GP of said cell membranes or part thereof by the following formula:
14. (canceled)
15. Method for in vitro and ex vivo evaluation of the response to a therapeutic treatment of a patient afflicted with a cancer, said therapeutic treatment being directed to said cancer, said method comprising the steps of: a) labelling a cell membrane or part thereof in a sample from a tumour of said patient obtained after said therapeutic treatment, with a fluorescent compound according to claim 1 by a method comprising a step of contacting a fluorescent compound according to claim 1 with a lipid membrane or part thereof, and a step of detecting the fluorescence of said lipid membrane or part thereof labelled by the said fluorescent compound, b) determining a generalized polarization parameter GP of said cell membrane or part thereof by the following formula:
16. Method for quantification of lipids organized in at least one lipid membrane or part thereof in an aqueous solution, comprising the steps of: a) labelling a lipid membrane or part thereof with a fluorescent compound according to claim 1 by a method comprising a step of contacting a fluorescent compound according to claim 1 with a lipid membrane or part thereof, and a step of detecting the fluorescence of said lipid membrane or part thereof labelled by the said fluorescent compound, b) measuring the intensity of fluorescence I.sub.lc by fluorimetry, typically by using a spectrofluorometer or a photomultiplicator, at a wavelength characteristic of said fluorescent compound in gel lipid phase, c) determining the concentration of said at least one lipid membrane or part thereof, by reporting the value obtained in step b) on a calibration curve of the fluorescence intensity as function of the concentration, the calibration curve being a hyperbolic function of the formula y=ax/(b+x) with y being the intensity of fluorescence and x the concentration of the at least one lipid membrane.
Description
LEGEND TO THE FIGURES
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223]
[0224]
[0225] Signatures were established from the RNAseq analysis of the metastable cell line. Intrinsic molecular subtype of each cell line is indicated wherein A represents luminal A cell lines, B represents luminal B cell lines, C represents claudin-low cell lines, D represents her2 cell lines and E represents basal cell lines.
[0226]
[0227]
[0228]
[0229]
[0230]
[0231]
[0232]
[0233]
[0234]
EXAMPLES
Example 1
Synthesis of DIOLL Probe
1. Chemicals and Reagents
[0235] Lauroylchloride and nitrobenzene were purchased from Acros. 2-bromonaphthalene, aluminium chloride, N-methylallylamine, 2-dicyclohexylphosphino2′4′6′triisopropylbiphenyl (X-Phos), Palladium acetate (Pd (Ac)2), N-methylmorpholine oxide monohydrate, catalytic OsO4 2.5% solution in tert-butanol and anhydrous dioxane were purchased from Sigma-Aldrich. Potassium tert-butanolate was purchased from Lancaster. Nitrobenzene and anhydrous dioxane were used without further purification. Flash chromatographies were performed on silica gel purchased from Acros Organics.
2. Synthesis
[0236] Reactions were carried out in dried glassware and under argon atmosphere. All reactions were magnetically stirred and monitored by thin-layer chromatography (TLC) on silica gel 60 F254 (Merck) plates using UV light to visualize the compounds. Yields refer to chromatographically and spectroscopically pure compounds unless otherwise noted. .sup.1H and .sup.13C NMR spectra were recorded at 23° C. using Bruker Avance DRX300, DRX400 or DRX500. Chemical shifts are reported relative to the residue peaks of the solvent (CDCl3: 7.26 ppm for .sup.1H and 77.16 ppm for .sup.13C). The following abbreviations are used to denote the multiplicities: s=singlet, d=doublet, dd=doublet of doublets, t=triplet, m=multiplet and br s=broad singlet. NMR solvents were purchased from Euriso-Top (SaintAubin, France). Low resolution mass spectra (ESI) and HRMS were recorded in positive ion mode using a Thermo Finnigan LCQ spectrometer.
a. Synthesis of 1-(6-bromonaphthalen-2-yl) dodecan-1-one
[0237] 2-bromonaphthalene (2 g, 9.7 mmol) was dissolved in 9.6 mL of nitrobenzene under an Argon atmosphere. The solution was stirred in an ice bath. Lauroylchloride (2.8 mL, 11.64 mmol, 1.2 equiv.) was added drop wise. The reaction mixture was treated with aluminium chloride (1.4 g, 10.67 mmol, 1.1 equiv.) and stirred at room temperature for at least 18 hours. The reaction mixture was quenched with distilled water and extracted three times with ethylacetate. The organic phases were combined, washed with brine, dried over sodium sulphate and concentrated under reduced pressure. The product was purified by crystallization from cold ethanol to obtain a yellowish powder; yield 1.6305 g (43.4%).
[0238] .sup.1H NMR (300 MHz, CDCl.sub.3): δ=0.88 (t, 3H, J=6.6 Hz, CH.sub.3); 1.26-1.37 (m, 16H, CH.sub.2); 1.79 (m, 2H, CH.sub.2); 3.07 (t, 2H, J=7.5 Hz, CH.sub.2CO); 7.62 (d, 1H, J=8.7 Hz, H ar); 7.81 (m, 2H, H ar); 8.05 (m, 2H, H ar); 8.42 (s, 1H, H ar).
[0239] .sup.13C NMR: δ=14.1; 22.7; 24.5; 29.4; 29.5; 29.6; 29.7; 31.9; 38.8; 122.7; 125.2; 127.5; 129.4; 129.9; 130.2; 131.0; 134.8; 136.4; 200.2.
[0240] HRMS: m/z (MH+) C.sub.22H.sub.30BrO calculated: 389.1475, measured: 389.1471.
b. Synthesis of 1-(6-(allyl(methyl)amino)naphthalen-2-yl)dodecan-1-one (NMAAL)
[0241] An oven-dried Schlenk flask was evacuated and backfilled with argon. The flask was charged with 1-(6-bromonaphthalen-2-yl) dodecan-1-one (200 mg, 0.514 mmol); (Pd (Ac).sub.2) (9 mg, 41.1 μmol, 0.08 equiv.); X-Phos (39 mg, 82.2 μmol, 0.16 equiv.) and cesium carbonate (503 mg, 1.54 mmol, 3 equiv.). The Schlenk flask was capped with a rubber septum, and then evacuated and backfilled with argon three times. N-methylallylamine (64 μL, 0.668 mmol, 1.3 equiv.) and anhydrous dioxane (1.5 mL) were added through the septum. The mixture was heated to 100° C. in an oil bath and stirred for 15 hours. The mixture was cooled down to room temperature, diluted with ethylacetate, filtered through Celite and concentrated under reduce pressure to obtain a brown solid product. The crude product was purified by flash chromatography on silica gel eluting with ethylacetate/petroleum ether=3/97. A yellow powder (51.5 mg, yield 21%) was obtained. The final product is pure at 80%.
[0242] .sup.1H NMR (300 MHz, CDCl.sub.3): δ=0.88 (t, 3H, J=5.1 Hz, CH.sub.3); 1.25-1.37 (m, 16H, CH.sub.2); 1.77 (m, 2H, CH.sub.2); 3.03 (t, 2H, J=7.7 Hz, CH.sub.2CO); 3.10 (s, 3H, NCH.sub.3); 4.07 (d, 2H, J=3.6 Hz, CH.sub.2N) ; 5.17-5.22 (m, 2H, CH.sub.2═CH); 5.89 (m, 1H, CH═CH.sub.2); 6.96 (br s, 1H, H ar); 7.16 (dd, 1H, J=6.6 Hz, J=1.2 Hz, H ar); 7.64 (d, 1H, J=6.6 Hz, H ar); 7.80 (d, 1H, J=6.9 Hz, H ar); 7.93 (dd, 1H, J=6.3 Hz, J=1.2 Hz, H ar); 8.32 (s, 1H, H ar).
[0243] .sup.13C NMR: δ=14.1; 22.7; 24.9; 29.3; 29.5; 29.6; 29.7; 31.9; 38.3; 38.4; 55.1, 116.2; 124.7; 126.1; 129.7; 130.7; 133.0; 137.6; 200.2.
[0244] HRMS: m/z (MH.sup.+) C.sub.26H.sub.38NO calculated: 380.2948, measured: 380.2938.
c. Synthesis of 1-(6-((2,3-dihydroxypropyl)(methyl)amino)naphthalen-2-yl)dodecan-1-one (DIOLL probe, compound of formula 12, referred herein as “DIOLL”)
[0245] The NMAAL (80% purity) product is disposed in 25 mL glassware. 5 mL of acetone, 2 mL of water, 141 mg of N-methylmorpholine oxide monohydrate and 50 μL of catalytic 0504 (100 μL of a 2.5% solution in tert-butanol) are added and the reaction is stirred overnight at room temperature. The mixture is then diluted in ethylacetate, extracted with water (2×30 mL) and washed with brine (30 mL). The organic phase is dried over magnesium sulphate and concentrated under reduce pressure to obtain a crude product purified by flash chromatography on silica gel. Elution is carried first with 100 mL of ethylacetate/petroleum ether (10/90) to eliminate contaminants, then with 100 mL ethylacetate/petroleum ether (50/50) to eliminate intermediate products of reaction and finally with 100 mL of ethylacetate 100% for the recuperation of a dark green pure final product (18.7 mg, yield 41.7%).
[0246] .sup.1H NMR (500 MHz, CDCl.sub.3): δ=0.88 (t, 3H, J=7.0 Hz, CH.sub.3); 1.25-1.41 (m, 16H, CH.sub.2); 1.77 (m, 2H, CH.sub.2); 3.03 (t, 2H, J=7.5 Hz, CH.sub.2CO); 3.14 (s, 3H, CH.sub.3N) ; 3.51 (dd, 1H, J=15 Hz, J=5.5 Hz); 3.61 (m, 2H); 3.82 (dd, 1H, J=11.5 Hz, J=3.5 Hz); 4.11 (m, 1H, CHO); 6.95 (br s, 1H, H ar); 7.22 (dd, 1H, J=9.5 Hz, J=2.5 Hz, H ar); 7.63 (d, 1H, J=8.5 Hz, H ar); 7.80 (d, 1H, J=9 Hz, H ar); 7.93 (dd, 1H, J=8.5 Hz, J=1.5 Hz, H ar); 8.32 (s, 1H, H ar).
[0247] .sup.13C NMR: δ=14.1; 22.7; 24.8; 29.4; 29.5; 29.6; 29.7; 31.9; 38.4; 39.5; 55.3; 64.2; 69.8; 105.9; 116.5; 124.8; 125.5; 126.3; 129.7; 130.9; 131.1 ; 137.5; 149.5; 200.3.
[0248] HRMS: m/z (MH.sup.+) C.sub.26H.sub.40NO.sub.3 calculated: 414.3003, measured: 414.2995.
Example 2
Labelling Lipid Membrane with DIOLL Probe
1. Material and Method
[0249] a. Chemicals
[0250] DIOLL probe was synthesis as described in Example 1.
[0251] Laurdan was purchased from GE healthsicences and C-Laurdan was synthesized as described below.
[0252] Lipids were purchased from Avanti Polar Lipids (Alabaster, Al.). PBS was purchased from Sigma-Aldrich. Ultrapure water was obtained with a PureLabOption Q7 system (Veolia Water STI, Decines, France).
[0253] Fetal bovine serum (FBS) was purchased from Eurobio (ref: CVFSVF 00-01), Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12 (DMEM/F-12) nutrient mixture (Ham) (ref: 31331-028) and penicillin-streptomycin were purchased from Gibco, human epidermal growth factor (EGF) was purchased from Promocell and insulin was purchased from NovoRapid.
[0254] Dil is purchased from life technologies (ref: M7513), Er-tracker is purchased from life technologies, Mito tracker is purchased from life technologies.
b. C-Laurdan Synthesis
i. Synthesis of 1-(6-Bromonaphthalen-2-yl)dodecan-1-one and 1-(6-chloronaphthalen-2-yl)dodecan-1-one
[0255] 2-Bromonaphthalene (4 g, 19.3 mmol) was dissolved in 20 mL of nitrobenzene under an argon atmosphere. The solution was stirred in an ice bath. Aluminium chloride (2.836 g, 21.23 mmol, 1.1 equiv.) was added by portions and lauroyl chloride (5.036 mL, 23.16 mmol, 1.2 equiv.) was added drop- wise. The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched with distilled water and extracted three times with ethyl acetate. The organic phases were combined, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The product was purified by crystallization from cold ethanol to obtain a white powder; yield 4.215 g (56%).
[0256] .sup.1H NMR (300 MHz, CDCl.sub.3): δ=0.88 (t, 3H, J=6.6 Hz, CH.sub.3); 1.26-1.37 (m, 16H, CH.sub.2); 1.79 (m, 2H, CH.sub.2); 3.07 (t, 2H, J=7.5 Hz, CH.sub.2CO); 7.62 (d, 1H, J=8.7 Hz, H ar); 7.81 (m, 2H, H ar); 8.05 (m, 2H, H ar); 8.42 (s, 1H, H ar). .sup.13C NMR: δ=14.1; 22.7; 24.5; 29.4; 29.5; 29.6; 29.7; 31.9; 38.8; 122.7; 125.2; 127.5; 129.4; 129.9; 130.2; 131.0; 134.8; 136.4; 200.2. HRMS: m/z (MH.sub.+) C.sub.22H.sub.30BrO calculated: 389.1475, found: 389.1471.
[0257] 2-Chloronaphthalene (1 g, 6.1 mmol) was dissolved in 6 mL of nitrobenzene under an argon atmosphere. The solution was stirred in an ice bath. Lauroylchloride (1.7 mL, 7.32 mmol, 1.2 equiv.) was added drop wise. The reaction mixture was treated with aluminium chloride (854 mg, 6.71 mmol, 1.1 equiv.) and stirred at room temperature for at least 18 hours. The reaction mixture was quenched with distilled water and extracted three times with ethylacetate. The organic phases were combined, washed with brine, dried over sodium sulphate and concentrated under reduced pressure. The product was purified by crystallization from cold ethanol to obtain a yellow powder; yield 1.06 g (50%). .sup.1H NMR (300 MHz, CDCl.sub.3): δ=0.88 (t, 3H, J=6.9 Hz, CH.sub.3); 1.26-1.41 (m, 16H, CH.sub.2); 1.79 (m, 2H, CH.sub.2); 3.07 (t, 2H, J=7.5 Hz, CH.sub.2CO); 7.49 (dd, 1H, J=8.7 Hz, J=2.1 Hz, H ar); 7.79-7.91 (m, 3H, H ar); 8.05 (dd, 1H, J=8.7 Hz, J=1.8 Hz, H ar); 8.43 (br s, 1H, H ar). .sup.13C NMR: δ=14.1; 22.7; 24.5; 29.3; 29.4; 29.5; 29.6; 31.9; 38.7; 125.1; 126.6; 127.6;
[0258] 127.7; 129.3; 130.8; 131.0; 134.3; 134.6; 136.0; 200.2. MS: m/z (MNa+)=367.2; HRMS: m/z (MH+) C.sub.22H.sub.30C.sub.10 calculated: 345.1980, measured: 345.1973.
ii. Synthesis of Ethyl 2[(6-dodecanoylnaphthalen-2-yl)methylamino]acetate
[0259] An oven-dried Schlenk flask was evacuated and backfilled with argon. The flask was charged with 1-(6-bromonaphthalen-2-yl) dodecan-1-one (1 g, 2.57 mmol), Pd(OAc)2 (46 mg, 206 mmol, 0.08 equiv.), X-Phos (196 mg, 411 mmol, 0.16 equiv.), cesium carbonate (3.35 g, 10.28 mmol, 4 equiv.), and sarcosine ethyl ester (790 mg, 5.14 mmol, 2 equiv.). The Schlenk flask was capped with a rubber septum, then evacuated and backfilled with argon three times. Anhydrous dioxane (7.5 mL) was added through the septum. The mixture was heated to 100° C. in an oil bath and was stirred for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate, filtered through Celite, and concentrated under reduced pressure to obtain a yellow solid. The crude product was purified by flash chromatography on silica gel eluting with ethyl acetate/petroleum ether (10/90) to afford a yellow powder (569 mg, yield 52%).
[0260] .sub.1H NMR (300 MHz, CDCl.sub.3): δ=0.88 (t, 3H, J=7.2 Hz, CH.sub.3); 1.21-1.36 (m, 16H, CH.sub.2); 1.76 (m, 2H, CH.sub.2); 3.00 (t, 2H, J=7.5 Hz, CH.sub.2CO); 3.16 (s, 3H, CH.sub.3N); 4.16 (s, 2H, COCH.sub.2N); 4.18 (q, 2H, J=7.2 Hz, CH.sub.3CH.sub.2O); 6.86 (d, 1H, J=2.4 Hz, H ar); 7.06 (dd, 1H, J=9.3 Hz, J=2.7 Hz, H ar); 7.62 (d, 1H, J=8.7 Hz, H ar); 7.78 (d, 1H, J=9.0 Hz, H ar); 7.92 (dd, 1H, J=8.7 Hz, J=1.8 Hz, H ar); 8.31 (br s, 1H, H ar). .sup.13C NMR: δ=14.1; 14.2; 22.7; 24.8; 29.3; 29.5; 29.6; 29.7; 31.9; 38.4; 39.8; 54.4; 61.2; 106.0; 114.6; 115.7; 124.7; 125.6; 126.4; 129.6; 130.8; 131.1; 137.4; 148.6; 170.4; 200.2. MS: m/z (MH+)=426.3. HRMS: m/z (MH+) C.sub.27H.sub.40NO.sub.3 calculated: 426.3003, found: 426.2988.
iii. Synthesis of 6-Dodecanoyl-2-[N-methyl-N-(carboxymethyl)amino] naphthalene (C-Laurdan)
[0261] 211 mg of ethyl 2[(6-dodecanoylnaphthalen-2-yl)methylamino] acetate was dissolved in 7 mL of a freshly prepared solution of potassium hydroxide (0.25 M) in ethanol. The reaction mixture was stirred for 2 days at room temperature. The solution was acidified with HCl (1 M) until pH 1 and was extracted with ethyl acetate (3×20 mL). The ethyl acetate layers were combined, dried over magnesium sulfate and concentrated under reduced pressure to obtain a brown solid which was purified by crystallization from chloroform/petroleum ether to provide 164 mg (83% yield) of C-Laurdan. .sup.1H and .sup.13C NMR and HRMS data of the product are identical with the published data (H. M. Kim, H. J. Choo, S. Y. Jung, Y. G. Ko, W. H. Park, S. J. Jeon, C. H. Kim, T. Joo and B. R. Cho, ChemBioChem, 2007, 8, 553-559).
c. Probe Fluorescence in Organic Solvents
[0262] Fluorescence measurements were performed with a Hitachi F4500 fluorometer. Excitation and emission slits were fixed at 5 nm and spectra were recorded at 25° C. using a 1 cm path length thermostated quartz micro-cuvette. 0.26 mM solutions of the probes were prepared in a dichloromethane: methanol mixture (3:1 volume ratio). Measurements were performed with 2.6 mM probes diluted in the different solvents (see Table 1). The initial solvent of the stock solution thus represents 1% of the final volume.
d. Probe Fluorescence in Liposomes
[0263] Liposomes were prepared in PBS buffer using a classical freeze/though protocol. In brief, lipids dissolved in chloroform were dried under vacuum. The lipid film formed was rehydrated with the PBS solution and agitated until the complete suspension of the lipid film. The vesicle solution was then submitted to 6 freeze/thaw (5 min in liquid nitrogen/10 min in 37° C. water bath) cycles and then extruded 19 times sequentially trough 400 nm and 200 nm polycarbonate membranes (Avanti Polar Lipids Liposome Extruder). The 200 nm liposome suspension was stored at 4° C.
[0264] Fluorescence data was obtained using a Hitachi F4500 fluorometer. Emission spectra were recorded between 420 and 600 nm with an excitation wavelength fixed at 385 nm and 5 nm excitation and emission slits. Ethanol solutions of fluorescent probes were prepared and added to liposomes at a 1:400 (probe: phospholipid) molar ratio. Liposomes were used at a 40 μg.mL.sup.−1 final concentration. Measurements were done at 21° C. for all liposome compositions indicated in Table 2, except for DMPC where a range of temperature from 5 to 65° C. was also applied.
e. Flow Cytometry
[0265] Fluorescence measurements were performed with an LSR Fortessa. Cells passing in front of the laser were exited with a laser of 405 nm and the filters 450/50 and 525/50 were used to respectively observed the rigid state intensity and fluid state intensity. Like the spectrofluorometer, Ethanol solutions of DIOLL were prepared and added to liposomes at a 1:400 molar ratio. Liposomes were used at a 40 μg.mL.sup.−1 final concentration. Measurements were done at 21° C. for all liposome composition indicated in Table 2. Data processing was effectuated on FlowJo.
f. Cell Culture
[0266] Human mammary epithelial cells (HMECs) were provided by Lonza. HMEC were cultured in 1:1 Dulbecco's Modified Eagle's Medium (DMEM)/HAMF12 medium (Gibco) complemented with 10% FBS (Gibco), 91 U.mL.sup.−1 penicillin-streptomycin (Gibco), 10 ng.mL.sup.−1 human epidermal growth factor (EGF) (Promocell), 262 mU.mL.sup.−1 insulin (NovoRapid) and 0,5 μg.ml.sup.−1 hydrocortisone (Sigma) under a humidified atmosphere of 5% CO.sub.2 at 37° C. Cell morphology and growth curve were routinely checked.
g. Confocal Microscopy Experiments
[0267] Cells were cultured in Lab-TEK® at 30% of confluence and DIOLL was added to obtain 0.5 μM 48 hours before observation.
[0268] 48 hours later cells were at 80% of confluence and ready for observation.
[0269] Specific organelle markers (plasma membrane (Dil), endoplasmic reticulum (ER tracker), mitochondria (Mito tracker)) were added 20 minutes before observation. Nuclear stain (Hoechst) was injected automatically in the chamber after DIOLL fluorescence recording.
[0270] The images were taken using a Zeiss LSM 880 AxioObserver inverted spectral confocal microscope. This is a spectral confocal microscope on stand with incubation chamber with environmental control temperature, CO.sub.2 and hygrometry. The light source is a laser diode. The objective is an alpha Plan-Apochromat 63x/1.46 Oil DIC M27.
[0271] For colocalisation experiments, DIOLL excitation wavelength was 405 nm and the emission wavelength was a band from 424 nm to 513 nm. For spectral mode acquisition excitation wavelength was 405 nm and images were taken at 424, 432, 441, 450, 459, 468, 477, 486, 495, 504, 513 nm emission wavelength.
[0272] For ER-tracker and Mito-tracker, the excitation wavelength was 561 nm and detection wavelength was 611 nm.
[0273] For DiI, the excitation wavelength was 561 nm and emission wavelength was 621 nm.
[0274] For Hoechst, the excitation wavelength was 405 nm and emission wavelength was 430 nm
h. Determination of the GP Parameter From the Images Obtained by Confocal Microscopy
[0275] A composite image was created from the image obtained with the DIOLL and the image obtained with one of the specific subcellular markers (Dil, ER-tracker, Mito tracker) to precisely identify areas were the probed colocalized. The emission intensity values in the 440 and 490 nm channels were measured using ImageJ after background correction for the areas identified. GP values were calculated with the same formula as for spectroscopy
experiments:
[0276] where I.sub.440 and I.sub.490 are recorded fluorescence intensities at wavelengths of 440 nm and 490 nm, respectively.
[0277] GP values were calculated from at least 5 independent measurements.
2. Results
[0278] a. Spectroscopic Properties of DIOLL Probe: A Comparison with Laurdan and C-Laurdan Probes in Organic Solvents of Increasing Polarity
[0279] The spectroscopic properties of DIOLL probe were compared to the one of Laurdan and C-Laurdan in organic solution (
[0280] Therefore, the same effect is searched for when alternative fluorophores are proposed: C-Laurdan and DIOLL probe perfectly respond to this requirement as shifts in the maximum emission wavelength are recorded with the increasing solvent polarity (416 nm and 425 nm in toluene, 432 and 441 nm in chloroform, 450 and 460 nm in DMSO and 485 nm and 486 nm in ethanol, for C-Laurdan and DIOLL probe, respectively).
TABLE-US-00001 TABLE 1 Maximum emission wavelength of Laurdan, C-Laurdan and DIOLL probe in organic solvents of increasing polarity. Solvent Probe Toluene Chloroform DMSO Ethanol λ emission Laurdan 423 440 460 485 maximum (nm) C-Laurdan 416 432 450 485 DIOLL 424 424 441 486 Maximum Laurdan 3814 4441 5533 4221 fluorescence C-Laurdan 359 3115 2428 1491 intensity (A. U.) DIOLL 5041 5041 9384 7647
[0281] Fluorescence intensity is however very different for the two Laurdan analogues, with DIOLL remarkably showing a high fluorescence intensity, going from 1.5 to 2 fold higher than for Laurdan whatever the solvent used. Inversely, C-Laurdan shows very low fluorescence intensities: 1.3 to 10 times lower than that of Laurdan (hypochromic effect). The good fluorescence yield recorded for DIOLL probe makes it a good candidate for microscopy and spectroscopy applications.
b. Fluorescence of DIOLL Probe in DMPC Liposomes
[0282] To check whether these promising fluorescence properties may serve for membrane state characterization, the inventors compared fluorescence properties of DIOLL probe with those of Laurdan and C-Laurdan in liposomes made of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC). This lipid is known to present a gel to liquid disordered phase transition at 24° C. that makes it a good model system to evaluate fluorophore capacity to evidence membrane fluidity changes, as PC phosphocholine is the main phospholipid in cell membranes.
[0283] The fluorescence spectrum of Laurdan inserted in DMPC liposomes evolved when temperature increased from 5° C. to 65° C. (
[0284] C-Laurdan in DMPC also shifts towards higher wavelength, but an overall decrease in the fluorescence intensity is recorded with the increase in temperature (
[0285] DIOLL has a behavior similar to Laurdan, with a shift in the maximum emission wavelength from 440 nm for the gel phase to 490 nm in the liquid crystalline phase (
[0286] Most of the commonly used fluorophores show better fluorescence intensity in the rigid (apolar) conditions, making thus the disordered contribution of the membrane underestimated. The good fluorescence yield of DIOLL probe in the disordered state, comparable with that obtained in the ordered state, opens the possibility of a more accurate quantification of the fluidity state of the membrane with respect to fluorophores commercially available to date.
[0287] The spectral shift described above was quantified by calculation of the Generalized Polarization (GP) parameter. This parameter provides a quantitative index of membrane fluidity and is calculated as the difference between fluorescence emission intensity at a 440 nm (lipids with gel properties) and the intensity at 490 nm (wavelength evidenced in lipids with liquid crystal properties), divided by the sum of these two intensities. The GP parameter was thus calculated from fluorescence emission intensities according to the following formula:
[0288] where I.sub.gel and I.sub.lc are, respectively, intensities of fluorescence at wavelengths characteristic of probe emission, respectively in gel and liquid crystal lipid phases.
[0289] Graphs of GP evolution as a function of temperature are plotted in
[0290] In conclusion, DIOLL and Laurdan show a large difference in GP values between the ordered/gel and disordered/liquid crystalline states. This property is of importance for microscopy use where a clear-cut separation of fluorescence coming from gel and liquid crystalline phases is required for visualization of membranes in different states.
[0291] The fluorescence intensities of DIOLL were compared with those of Laurdan and C-Laurdan, at 25° C. and a final concentration of 0.2 μM, in liposomes constituted of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), which occurs as one of the main phospholipids in cell membranes (
c. Degree of Order Quantification in Liposomes by Fluorescence Spectroscopy and Flow Cytometry Using DIOLL
[0292] As membrane fluidity state is determined by lipid acyl chain length and unsaturation, the inventors checked whether DIOLL was equally able to render variations in membrane state depending on lipid characteristics. Therefore, DIOLL was inserted in liposomes constituted of phosphatidylcholines with different melting temperatures, dictated by different chain length and unsaturation (ranging from 14 to 18 carbons for the chain length and from 0 to 2 for the chain unsaturation, respectively; Table 2).
[0293] Fluorescence spectra were registered and GP parameter was measured at 21° C.
TABLE-US-00002 TABLE 2 Liposome preparations used and corresponding phase transition temperatures (Tm). Liposome Acyl chain preparation Lipid composition Schematic structure Tm DLPC 1,2-dilinoleoyl- sn-glycero-3- phosphocholine 18:2 (Δ.sup.9,12- Cis) PC
[0294] Results plotted in
[0295] Moreover, the new fluorophore proved to be an excellent tool to measure liposome fluidity by flow cytometry. This technique allows one to visualize and discriminate events (cells or particles) within a heterogeneous population via differences of size, granularity or fluorescence. Unlike the spectrofluorometer, which gives a bulk fluorescence spectrum and thus a bulk value of GP, by using flow cytometry, one may obtain the GP parameter of individual particles in a heterogeneous population.
[0296] To take advantage of a routine flow cytometer, the inventors replaced the GP parameter by the ratio 525 nm fluorescence emission intensity (corresponding to the fluid phase emission) on 450 nm fluorescence emission intensity (corresponding to the gel phase emission) which is equivalent to a ratio fluid state intensity on rigid state intensity. Results are plotted in
[0297] Indeed, the correlation GP and fluidity state observed through spectroscopy is also found with a flow cytometer. The entire fluidity range is discriminated with the DSPC liposomes, theoretically the most rigid at 21° C., which has a lowest ratio 525/450, while the DLPC liposomes which the most fluid has a highest ratio 525/450.
d. Labelling of Membranes with DIOLL Probe as a Function of Their Fluidity State
[0298] To check whether the probe empirically distinguishes differences in membrane fluidity in cell membranes, HMEC cells were incubated with DIOLL probe for 48 h and then observed by confocal microscopy. Fluorescence images were recorded each 10 nm from 425 to 512 nm (excitation 405 nm). DIOLL labeled uniformly all cell membranes, yet the fluorescence profile was different for each emission channel, with membrane structures that were more intensively labeled in the blue edge and others in the red edge of the spectrum. An overlay of images obtained is shown in
[0299] Different shades of grey corresponding to different fluorescence intensity obtained in each channel leads to the differentiation of the fluidity state of the cell membranes. To precisely identify plasma and organelle membranes, co-localization experiments with specific organelle markers were performed. DIOLL fluorescence co-localized at the plasma membrane level with membrane label Dil. DIOLL also showed a good co-localization with ER-tracker, which is a specific label of the endoplasmic reticulum. It also co-localized with Mito-tracker, a specific label of mitochondria. Of note, DIOLL perfectly labels membrane structures of the nucleus. Nuclear content was labeled with Hoechst.
[0300] From DIOLL membrane labelling, GP values were estimated from the relative intensities at 440 and 490 nm for each type of membrane identified above (
Example 3
Quantification of Lipid Membranes in Aqueous Solutions
[0301] Liposomes, various supported or tethered bilayers, monolayers, bicelles, to name only some, are largely used systems to mimic plasma and organelle membranes.
[0302] Among such models, liposomes are widely used to probe protein-lipid interactions, lipid organization and molecule penetration across membranes. They are also versatile assemblies in drug delivery systems, as they are non-toxic, biodegradable, and readily produced on a large scale. They are also extensively used for the reconstitution of transmembrane proteins, to form proteoliposomes, the lipid bilayer offering a native-like medium for membrane-spanning domains. For all these applications, liposomes undergo various fabrication processes: extrusion, centrifugation, protein reconstitution, cell-free protein synthesis, molecule grafting, etc. It is therefore of interest to determine lipid concentrations after various processes and in different production batches.
[0303] To estimate liposome concentration, several methods are popular. Among them, colorimetric methods such as Bartlett. and Rouser. methods are based on the reaction between the inorganic phosphate obtained after liposome treatment with perchloric acid and ammonium molibdate to obtain phosphomolibdate. The addition of a reducing agent such as 1-amino-2-naphtol-4 sulfonic acid (Bartlett method) and ascorbic acid (Rouser method) leads to formation of a violet complex absorbing at 820-830 nm. Both methods are rather sensitive (LOD and LOQ around 5 and 20 μg.ml.sup.−1, respectively). Alternatively, the Stewart method (Stewart, Analytical Biochemistry 104, 10-14 (1980)) probably the most widely used method for phospholipid determination, is based on the formation of a complex between the phosphate group of the lipid polar head and ammonium ferro-thiocyanate, absorbing at 485 nm. It is rather fast and easy to implement, but requires lipid extraction in organic solvent and the use of chloroform-resistant recipes and protection. LOD and LOQ methods are evaluated at 10 μg.ml.sup.−1 and 100 μg.ml.sup.−1, respectively.
[0304] Chromatographic methods of lipid separation, together with mass spectroscopy or NMR are also methods of choice for lipid detection and quantification, as one can obtain not only the lipid amount, but also lipid class distribution. Yet, they are time consuming, rather expensive and not readily used in routine experiments.
[0305] Given the number of studies dwelling on liposomes, proteoliposomes and on cell-derived vesicles, the inventors propose a simple method to estimate the amount of membranes in aqueous solutions.
1. Material and Method
[0306] a. Materials
[0307] DIOLL probe was synthesis as described in Example 1.
[0308] Lipids were purchased from Avanti Polar Lipids (Alabaster, Al.). Hepes, PBS, NaCl, ferric chloride hexahydrate (FeCl.sub.3(H.sub.2O).sub.6) and ammonium thiocyanate (NH.sub.4SCN) were purchased from Sigma Aldrich (St Quentin Falavier, France). Ultrapure water was obtained with a PureLabOption Q7 system (Véolia Water STI, Decines, France).
b. Methods
i. Liposome Preparation
[0309] Liposomes were prepared using a classical freeze/thaw protocol. Briefly, the appropriate lipid mixture solubilized in chloroform was dried under vacuum, then solubilized with 1 ml buffer under strong agitation. Assays were done either in HEPES 20 mM pH 7.4 buffer 100 mM NaCl or in PBS. The liposome emulsion obtained was submitted to 6 freeze/thaw cycles (5 min in liquid nitrogen/10 min in a water bath at 37° C., 1 minute strong agitation) to decrease the number of bilayers and obtain unilamellar vesicles. To obtain homogenous vesicles, the liposome solution was extruded successively through a 400 nm and 100 nm polycarbonate membrane using an extruder (Avanti Polar Lipids). Liposomes were routinely prepared at lipid concentrations between 1 and 10 mg.ml.sup.−1 and subsequently diluted at the desired concentration.
ii. DIOLL Probe Fluorescence-Based Liposome Quantification
[0310] A POPC solution of known concentration (100 μg.ml.sup.−1) was used as standard. Increasing volumes of the standard solution were diluted with buffer in a 96 well plate (Nunc). The final volume per well was 200 μl and lipid concentrations between 0 and 80 μg.ml.sup.−1 were used. Samples were prepared in parallel to a final volume of 200 μl per well.
[0311] A constant volume of DIOLL solution in ethanol (5 μl) was added in each well to obtain a final DIOLL concentration of 2 μM. The volume of ethanol added represented 2.5% of the final volume and had no effect on liposome integrity. The plate was incubated at room temperature for 10 min. Fluorescence emission spectra were recorded between 420 nm and 600 nm for an excitation wavelength of 390 nm with a TECAN InfiniteM200 plate reader. Spectra were recorded at 21° C.
[0312] The surface under the spectrum was calculated for each condition using an Excel complementary function, IntegralP (www.fordom.free.fr) which allows one to calculate the integral of a function when discrete data sets are available. Maximum fluorescence intensities or surfaces under the curve were plotted as a function of the lipid concentration to obtain the standard curve. They both show a hyperbolic variation and the equation of the standard curve was obtained using a hyperbolic fit y=ax/(x+b) (SigmaPlot). The calculation of the a and b coefficients allowed us to determine unknown concentrations in the samples. As various volumes were used for the assays, the concentration of the stock liposome solution was presented taking into account various dilution factors. Measurements were performed in triplicates.
[0313] For the estimation of the limit of detection (LOD) and of quantification (LOQ), the fluorescence spectra of 2 μM DIOLL in aqueous buffer were recorded in the absence of liposomes and the surface under the curve was calculated to estimate the blank value on 5 independent measurements. LOD and LOQ were calculated as 3 times or 10 times the standard deviation of the blank, respectively.
[0314] Sensitivity was estimated from the slope of the linear fit for low liposome concentrations. As the fluorescence intensity is dependent on the instrument used, in this study the inventors estimated that an increase of 100 A.U. in the fluorescence intensity obtained with TECAN InfiniteM200 was significant.
[0315] To conclude upon the repeatability of the method, the coefficient of variation (CV) was calculated as the percentage of the standard deviation on the mean of 5 independent measurements. Accuracy was deduced from the difference between the concentrations obtained with the DIOLL-based method and a standard method of phospholipid quantification, in our case the Stewart method.
[0316] For the Stewart method, lipids were extracted from the various samples with chloroform. In brief, aqueous samples were mixed with chloroform (10 times the volume of the sample) under vigorous shaking. The samples were then centrifuged at 300×g for 10 min to accelerate phase separation (Multifuge 3 LR, Heraeus). The chloroform (bottom) phase was recovered with a glass pipette.
[0317] A POPC standard solution was prepared at 100 μg.ml.sup.−1 in chloroform. Increasing volumes of the standard solution were diluted with chloroform in glass centrifuge tubes to a final volume of 2 ml. Samples extracted in chloroform were prepared in parallel and diluted to 2 ml. 2 ml of Ferrothiocyanate solution (obtained by mixing 20.7 g of Ferric chloride hexahydate and 30.4 g of ammonium thiocyanate in 1L of ultrapure water) was added to each tube. The solutions were vigorously mixed and then centrifuged at 300×g for 10 min (Multifuge 3 LR, Heraeus). The chloroform (bottom) phase was recovered with a glass pipette and the absorbance was measured at 485 nm in glass cuvettes with a Jasco V-730 spectrophotometer. For quantification absorbance at 485 nm was plotted against phospholipid concentration.
iii. Purification of exosomes
[0318] The purification of exosomes was realized by a series of differential centrifugations. In brief, 120 ml of HMEC culture medium were collected after two days of culture, and centrifuged at 2 000×g at 4° C. during 10 min (Multifuge 3LR Heraus™). Supernatants were collected and ultracentrifuged at 20 000×g, 4° C. during 30 min (Optima LE-80 Beckman™ with a fixed rotor angle 50.2 Ti Beckman™). A second ultracentrifugation was realized at 100 000×g, 4° C. during 2 h. Pellets were resuspended with 1 mL of PBS buffer, regrouped in the same tube and ultracentrifuged at 100 000×g, 4° C. during 1 h. Finally, the pellet was resuspended in 200 μL of PBS buffer to obtain concentrated exosomes.
iv. Giant Plasma Membrane Vesicles Preparation
[0319] Giant Plasma Membrane Vesicles (GPMV) were prepared according to previously described protocol (Baumgart, T. et al. Large-scale fluid/fluid phase separation of proteins and lipids in giant plasma membrane vesicles. Proc. Natl. Acad. Sci. (2007). doi:10.1073/pnas.0611357104) but adapted to PC-3 cell culture. In brief, PC-3 were cultured in RPMI-1640 10% FBS 100 U/mL penicillin and 100 μg/mL streptomycin under a humidified atmosphere of 5% CO.sub.2 at 37° C. at 80% cell confluence in 25 cm.sup.2 plastic flasks. Growth medium was removed and cells were incubated for 1 h with 25 mM formaldehyde 2 mM DTT in PBS buffer at room temperature under shaking. The supernatant containing GPMVs was recovered and the presence of GPMVs was checked with an optical microscope. For DIOLL-based measurements, 200 μl of the GPMV preparation was incubated with 5 μl DIOLL probe ethanol solution (2 μM final concentration) and fluorescence spectra were recorded as described above. The lipid concentration was determined against a standard curved obtained with POPC liposomes of known concentration.
2. Results
[0320] a. Quantification of Liposomes Using DIOLL Probe
[0321] To probe the dependency of DIOLL probe fluorescence upon liposome amount, increasing concentrations of POPC liposomes were incubated with a constant concentration of 2 μM DIOLL. Fluorescence spectra were recorded and plotted in
[0322] The limit of detection (LOD), the lowest concentration that can be detected but not quantified, and the limit of quantification (LOQ), the lowest concentration that can be quantified with a reasonable degree of confidence, of the calibration curve were determined from the standard deviation of the blank solution (2 μM DIOLL in buffer) (Table 3). The LOD, which corresponds to the lipid concentration obtained at 3 times the standard deviation of the blank, which was of 0.4 μg.ml.sup.−1, whereas the LOQ corresponded to a lipid concentration of 1.2 μg.ml.sup.−1 obtained for 10 times the standard deviation of the blank. These limits are rather low and make this method interesting for measuring low liposome concentrations, when small or diluted sample volumes are available.
TABLE-US-00003 TABLE 3 Validation of the detection method LOD LOQ Sensitivity Repeatability Accuracy 0.4 μg.ml.sup.−1 1.2 μg.ml.sup.−1 10 000 (A.U) 0.4 μg.ml.sup.−1 1.2% 6.0%
[0323] The sensitivity of the detection method is defined as the dependency between the instrumental response and the variation in the concentration of the compound of interest. It is instrument-dependent. In our conditions, the slope of the linear part was equal to 10.sup.5 A.U (arbitrary unit). per concentration unit (μg.ml.sup.−1). That means that, considering that the sensitivity limit of TECAN InfiniteM200 used in this study is 100 A.U., one can detect variations in liposome concentration of the sample as low as 1 ng.ml.sup.−1.
[0324] The repeatability of the method, which represents the determination of how close values are to each other, under identical experimental conditions, was assessed by determination of the concentration of a POPC liposome solution prepared independently of the standard solution. A concentration of 914±56 μg ml.sup.−1 was obtained with 3 replicates, which gave a repeatability of 6%. To assess the accuracy of the new quantification method, the same POPC liposome solution was measured using the largely used Stewart method. A difference of 1.2% was obtained between mean values obtained with the two methods. Results were therefore consistent and opened the possibility to routinely use the DIOLL as a probe to measure lipid membrane amount in various samples, without lipid extraction and in a rather short time (less than 30 min).
[0325] Robustness of the DIOLL method was checked with respect to various parameters. One major point of interest was whether the membrane fluidity, which largely influences DIOLL fluorescence, had an impact on the DIOLL-based quantification method. To this purpose, liposomes constituted of DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DPPC (1,2-dipalmitoyl-glycero-3-phosphocholine) were prepared (Table 4).
TABLE-US-00004 TABLE 4 Liposome preparations used and corresponding phase transition temperatures (Tm) Liposome Acyl chain preparation Lipid composition Schematic structure Tm POPC 1-palmitoyl-2- oleoyl-glycero-3- phosphocholine 16:0-18:1 PC
[0326] In our experimental conditions (21° C.), DMPC (gel to liquid crystalline transition temperature (Tm) of 23° C.) is expected to be in an ordered state, but close to the liquid ordered-liquid disordered transition, and DPPC (Tm 41° C.) in an ordered configuration. Independently, a standard liposome solution was prepared for each type of liposomes to obtain the corresponding calibration curves. DMPC-inserted DIOLL fluorescence spectra (
[0327] To check the influence of the membrane fluidity on the quantification method, POPC, DMPC and DPPC liposomes were prepared and their concentration was determined using either POPC, DMPC or DPPC calibration curves or by the Stewart method with POPC in chloroform solution as standard. Results are presented in
[0328] Cholesterol is one major component of membranes and also a major modulator of membrane order. Depending on membranes, the proportion of cholesterol varies between 10 and 30% of lipid total mass. Liposomes containing a mixture of POPC and cholesterol where prepared and the concentration was measured using DIOLL method and POPC liposomes of known concentration as a standard curve. The concentration obtained for 10, 20 and 30% cholesterol correlated well with the concentration of phospholipids obtained using the Stewart method (
[0329] Membranes contain non negligible amounts of negatively charged lipids with precise and fundamental functions. It is thus of interest to check the robustness of the DIOLL-based quantification method towards negatively charged lipids. As an example, the inventors have chosen to prepare liposomes containing 50% POPC and 50% POPS (1-palmitoyl-2-oleoyl-glycero-3-phosphoserine). The concentration of the prepared liposome solution was estimated either by the DIOLL-based method, with POPC liposomes of known concentration as standard curve, either by the Stewart method with POPC chloroform solution as standard (
[0330] To sum up, by using the surface under the curve parameter instead of the fluorescence emission intensity, the new fluorescence-based quantification method of membrane proved to be robust with respect to the order state of the membrane. By using a simple standard curve such as plain liposomes of increasing concentration and a constant fluorophore concentration, one can determine membrane amount in samples of different compositions: DMPC, DPPC, cholesterol-containing liposomes or negatively charged liposomes.
b. Quantification of Exosomes Using DIOLL Probe
[0331] Exosomes are small vesicles (50 to 150 nm) secreted by cells, specific of their origin cell and which can be extracted from numerous body fluids (blood, urine . . . ). They are therefore of interest for studies of pathologies, but also for the development of non-invasive diagnostic tools, notably in oncology. Measuring exosome concentration rapidly, with small sample volumes and in a non-destructive manner is of growing interest. Therefore, the inventors adapted the DIOLL-based quantification method to this type of vesicles. A standard curve based on POPC liposomes of known concentration in the presence of a constant DIOLLconcentration (2 μM) was recorded as the surface under the curve vs. liposome concentration in the well, as described above. Exosome samples were incubated with the same DIOLL concentration as the standard solution and the surface under the curve was calculated. Vesicle concentration was obtained using a hyperbolic fit of the standard curve and correlated with phospholipid determination using Stewart method (98±10 μg.ml.sup.−1 vs 102±10 μg.ml.sup.−1) (
c. Quantification of GPMVs Vesicles Using DIOLL Probe
[0332] A second type of vesicles used was obtained from living cells by plasma membrane budding. GPMVs are derived from biological cells, by chemically induced (here with 25 mM formaldehyde, 2 mM DTT in PBS) plasma membrane vesiculation or “blebbing”.
[0333] This type of vesicles is largely used to analyze phase coexistence in systems with realistic biological membrane compositions or peptide penetration across membranes. Given the raising interest in the study of plasma membrane heterogeneities, the inventors determined the amount of membranes in the GPMVs samples. As expected from literature data, GPMVs obtained by this method show simple, low-curvature geometries of giant unilamellar vesicles and appear free of cytoskeletal constraints. Using DIOLL fluorescence a lipid concentration of 84±1 μg.ml.sup.−1 was obtained from an estimated PC-3 cell population of 5 million. Using the Stewart method, a good correlation was observed with an estimated phospholipid sample concentration of 87±1 μg.ml.sup.−1 (
3. Discussion
[0334] Quantification methods of membrane content in various samples are scarce and require either lengthy protocols involving lipid extraction and costly instruments (GC, MS, NMR), organic solvents or energetic conditions.
[0335] The inventors present a new, rapid and easy to use method of lipid membrane quantification in artificial and natural vesicles based on the fluorescence of DIOLL probe. This fluorophore has a very low fluorescence in aqueous buffers, but when it spontaneously inserts into lipid bilayers its fluorescence drastically increases. the inventors checked therefore whether this was a regular increase, by incubating a constant amount of fluorophore with increasing amounts of liposomes. As shown in
[0336] To check this hypothesis, 3 types of liposomes were prepared with lipids with different ordering degrees at room temperature (23° C.): POPC (fluid state), DMPC (phase transition) and DPPC (gel state). The amount of liposomes was quantified using as standards either liposome solutions of the same nature, either liposome solutions of different fluidity. Quantification results (
[0337] Detection and quantification limits of the POPC standard curve attained values as low as 0.4 and 1.2 μg.ml.sup.−1, comparable with those of Bartlett and Stewart methods, which allows one to quantify low amounts of biological samples. Although a fluorophore is inserted into the bilayer, this method is not destructive and liposomes, proteoliposomes or diverse vesicles may be used for further applications. The sensitivity of the method was good up to 40 μg.ml.sup.−1. Above this value, the intensity of fluorescence reaches a plateau and samples require dilutions. The sensitivity of the method depends on the instrumental response to the variation in the analyte concentration, therefore it is instrument-dependent. In our conditions, by using an instrument such as TECAN InfiniteM200, the inventors detect variations in the liposome concentrations the range of 1 ng.ml.sup.−1.
[0338] Robustness of the detection method was checked with respect to the presence of cholesterol (
[0339] To conclude, DIOLL fluorescence can be used as a parameter to measure the amount of phospholipid membranes in complex samples without solvent extraction and that by using simple liposome compositions as standards. The detection method, based on fluorescence, is fast (less than 30 min with a plate reader, less than 1h with a classical fluorimeter), simple to use, sensitive and realizable with standard lab equipment.
Example 4
Fluidity Characterisation of Nanoemulsions Preparation with DIOLL Probe
1. Materials and Methods
[0340] a. Material
[0341] DIOLL probe was synthesis as described in Example 1.
[0342] Medium chain triglycerides, MCT (Miglyol®812) purchased from CREMER OLEO GmbH & Co. KG (Hamburg, Germany) was used as the oil phase. Polyoxyethylene (40) stearate (Myrj®52) from Sigma-Aldrich (St Quentin-Fallavier, France) and oleoyl polyoxyl-6 glycerides (Labrafil®M1944CS) from Gattefossé (Saint-Priest, France) were used as non-ionic surfactants. The aqueous phase used to prepare emulsions was sodium phosphate buffer solution (5 mM; pH 7.4). Tacrolimus (FK-506) was purchased from LC Laboratories (Woburn, Mass., USA). Hydrochloric acid 37%, AnalaR NORMAPUR® Reag. Ph. Eur. was from VWR International (Fontenay-sous-Bois, France). Dichloromethane, methanol, acetonitrile (HPLC grade), dodecyl sulfate sodium salt pure, sodium taurocholate hydrate 96% and sodium hydroxide were purchased from Fisher Scientific (Illkirch, France). Egg phospholipids with 70% phosphatidylcholine (Lipoid E80S) were from Lipoid GmbH (Ludwigshafen am Rhein, Germany). Acetic acid was obtained from Chem-Lab NV (Zedelgem, Belgium). Maltodextrin MD (Glucidex® 12D) from Roquette Freres (Lestrem, France) and trehalose 100 (TR) as a gift of Hayashibara Co. Ltd (Okayama, Japan) were used as cryoprotectants in the drying studies. Milli-Q water, used as the aqueous phase to prepare all solutions and emulsions, was obtained using a Milli-Q Academic System (Millipore, Saint Quentin, Yvelines France).
b. Methods
i. Nanoemulsion Preparation
[0343] Nanoemulsions (NE) were prepared by emulsion phase inversion (EPI) technique. The oil phase was prepared by mixing the oil (MCT) and surfactants (Polyoxyethylene (40) stearate: S1; and oleoyl polyoxyl-6 glycerides: S2) under magnetic stirring (750 rpm) at 80° C. Then, the aqueous phase (PBS 5 mM), heated up at 80° C. as well, was added all at once into the organic melt phase. Stirring was performed using a rotor-stator disperser (T25 digital Ultra-Turrax® equipped with a S25N-8G shaft (IKA®-Werke GmbH & Co. KG, Staufen, Germany) at 11,000 rpm. The process was designed so that the final emulsion always had a total mass of 5 g. The resulting colloidal system was cooled to room temperature under magnetic stirring during 30 min.
ii. Determination of NE Fluidity
[0344] The fluidity of the NE shell was determined by means of DIOLL probe. The DIOLL probe was dissolved in ethanol (263 μM). NE was diluted 1:1000 (0.027% w/v). 10 pL of DIOLL solution was added to 1 mL NE to reach a 2.6 μM final concentration of DIOLL, corresponding to a DIOLL-NE ratio of 1:290 (w/w) The sample was incubated for 20 min at room temperature. As controls, the fluorescence of DIOLL solutions (2.6 μM) in MCT and in water, and the fluorescence of blank NE (without DIOLL) were recorded. In this case, 10 μL of ethanol was added to 1 mL NE. Fluorescence data were obtained using a FP-8500 spectrofluorometer (JASCO applied science, Halifax, Canada). The excitation wavelength was 390 nm and the emission spectra were recorded between 400 and 600 nm at several temperatures ranging from 5 to 27° C. in steps of 2° C. and at 37° C. (2.5 nm bandwidth). The generalized polarization (GP) parameter was calculated from emission intensities according to:
[0345] where I.sub.440 and I.sub.400 are recorded fluorescence intensities at wavelengths of 440 nm and 490 nm, respectively.
2. Results
[0346] Fluorescence measurements using polarity sensitive fluorophores were performed. Laurdan (6-dodecanoyl-2-dimethylaminonaphthalene) is a polarity sensitive fluorophore commonly used for the assessment of liposomes rigidity and the study of biological membranes. Yet, when incubated with NE solution, its fluorescence emission spectrum was characteristic of a highly hydrophobic environment, single peak at 440 nm, suggesting that the fluorophore was inserted in the hydrophobic core of the NE.
[0347] DIOLL probe was post-inserted in the NE shell by simple mixing the probe with the NE suspension (DIOLL-NE). Insertion of DIOLL in the NE shell was checked by measurements of emission spectra of controls. Due to the lack of fluorescent activity in hydrophilic environment, no fluorescence emission was detected when the probe was dissolved in water. Neither blank NE emitted fluorescence. A single peak at 440 nm was observed when DIOLL was dissolved in MCT related to the radiative de-excitation of a “locally excited” state of DIOLL in oil. Emission spectra of DIOLL-NE at temperatures ranging from 5° C. to 37° C. showed two peaks at 440 nm and 490 nm, (
[0348] Decreasing the temperature from 37° C. to 5° C. led to the progressive increase of peak intensity at 440 nm (
Example 5
Dynamic Following of Cell Membrane Fluidity through a Nutritive Stimulus with DIOLL Probe
1. Material and Method
[0349] a. Chemicals
[0350] DIOLL probe was synthesis as described in Example 1.
[0351] Fetal bovine serum (FBS) and Horse serum were purchased from Eurobio (ref: CVFSVF 00-01, S090H-500), Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12 (DMEM/F-12) nutrient mixture (Ham) (ref: 31331-028) and penicillin-streptomycin were purchased from Gibco. Human epidermal growth factor (EGF) was purchased from Promocell and insulin was purchased from NovoRapid. Palmitate and BSA were purchased from Merck (Sigma).
b. Confocal Microscopy Experiments
[0352] Cells were cultured in Lab-TEK® at 30% of confluence and DIOLL was added to obtain 0.5 μM 48 hours before observation. During this time, cells were either incubated, 16 h just before the observation, in control medium with 10% SVF or in medium containing Horse serum (10%) or in medium containing 10% SVF and 500 μM of palmitate complexed with BSA (ratio 4/1) to maintain its solubility in acqueous solution.
[0353] 48 hours later, cells were at 80% of confluence and ready for observation.
[0354] The images were taken using a Zeiss LSM 880 AxioObserver inverted spectral confocal microscope. This is a spectral confocal microscope on stand with incubation chamber with environmental control temperature, CO.sub.2 and hygrometry. The light source is a laser diode. The objective is an alpha Plan-Apochromat 63x/1.46 Oil DIC M27.
[0355] For spectral mode acquisition excitation wavelength was 405 nm and images were taken at 424, 432, 441, 450, 459, 468, 477, 486, 495, 504, 513 nm emission wavelength.
c. Determination of the GP Parameter from the Images Obtained by Confocal Microscopy
[0356] A mask was created from the image obtained with the DIOLL by selecting alighted pixels from the background. From this mask, the emission intensity values in the 440 and 490 nm channels were measured using ImageJ. GP values were calculated with the same formula as for spectroscopy experiments:
[0357] where I.sub.440 and I.sub.490 are recorded fluorescence intensities at wavelengths of 440 nm and 490 nm, respectively.
[0358] GP values were calculated from at least 5 independent measurements.
2. Results and Discussion
Measuring Fluidity Change Dynamically After a Nutritive Stimulus
[0359] To check whether the probe is able to characterize a modification of membrane fluidity after a brief natural stimulus, the inventors verified the ability of the probe to detect and mesure the changes associated to a metabolic perturbation through the nutritive environement of the cells.
[0360] For that, the inventors treated HMEC cells with different media containing different spectrum of natural lipids. Horse serum has been well characterized for its high content in polyunsaturated lipid, at the difference of calf serum containing more saturated and monounsaturated lipids. Therefore, by taking these lipids from their extracellular environement, cells modify dynamically their lipids content into their membranes leading to rapid modification of their fluidity, not related in this case to a complicated genetic regulation. To obtain a counterpart to the Horse serum stimulus, the inventors also treated cells with palmitate, the most commun saturated fatty acid, to induce an opposite rapid rigidification of cell membranes. HMEC cells loaded with DIOLL 36 h before the start of the stimulus were thus briefly (16 h) incubated with these different conditions, and then observed by confocal microscopy. Fluorescence images were recorded each 10 nm from 425 to 512 nm (excitation 405 nm). Different shades of grey corresponding to different fluorescence intensity obtained in each channel leads to the differentiation of the fluidity state of the cell membranes.
[0361] As demonstrated in
Example 6
Distinguishing Cancer Cells from Healthy Cells with DIOLL Probe
[0362] A large number of pathologies originate in the deregulation of cellular differentiation processes leading to the appearance of non-adapted phenotypes, a phenomenon summarized as abnormal cellular genetic plasticity such as pulmonary, hepatic or cardiac. The mechanisms driving these processes are complex and rely heavily on epigenetic control of the genome. These epigenetic controls can be influenced by environmental stresses such as infections, toxicological agents or poor nutrition, but also by intrinsic genetic alterations such as those found during tumour development.
[0363] In general, cancer cells have greater genetic plasticity than healthy cells. However, there are different expressions of this plasticity which are difficult to quantify since only in vitro functional tests can measure the ability of cancer cells to modulate their differentiation program according to the signals imposed on them. On the other hand, a large amount of data from the literature suggests that the fluidity of cancer cell membranes is increased. the inventors thus assumed that, in general, the fluidity of the biological membranes could represent the degree of plasticity of the cell, thus allowing the measurement of a plasticity index based on a biophysical parameter that can easily be quantified by DIOLL probe.
[0364] In order to demonstrate and validate this concept, the inventors used cancer cells from two different tissues, but with common characteristics allowing their comparison: the mammary gland and the prostate. Among these characteristics, it is possible to highlight the existence of different forms of tumours with varying and well-characterized degrees of dedifferentiation. On one hand, little aggressive tumours can retain their glandular structure and on another hand, cells can retain their dependence on hormones, while conversely, the most aggressive tumours are hormone-independent and totally unstructured. Finally, there are pathologies in which cancer cells are no longer only dedifferentiated, but also acquire new phenotypes that are outliers in relation to their original tissue. These tumours testify that after having seen a sharp increase in their genetic plasticity, the phenotype of cancer cells is fixed in an abnormal state and different from their original state, which is then a priori characterized by a reduction in their plasticity.
[0365] DIOLL probe was synthesis as described in Example 1.
1. Distinguishing Mammary Gland Cell Lines with Known Various Degree of Genetic Plasticity as Function to their Membrane Fluidity
[0366] In order to validate the use of the DIOLL probe to measure the plasticity of cancer cells, the inventors first generated a cell line with a strong increase of its genetic plasticity. Non cancerous human mammary epithelial cells (HMEC) have been transduced by a genetic construct encoding ZEB1, under the control of a promoter repressed in the absence of doxycycline in the cell medium. ZEB1 is an embryonic transcription factor normally expressed in mammary adult stem cell. In this system, its induction can be controlled through cell incubation with doxycycline at 2 μg/ml, leading to a sharp dedifferentiation process and a lost of epithelial identity, a strong marker of cell plasticity. The inventors first verified that ZEB1 activation induced this transient phenotype correlated to an increase of membrane fluidity. Spectrofluorimetry and flow cytometry after simultaneous DIOLL incubation both confirmed the higher fluidity of cells loosing their identity(
[0367] Then, since this phenotype is normally very unstable and transient, the inventors designed an home-made protocol to fix this unstable state through simultaneous cell incubation in controlled nutrient medium (Glutamine 0.5 mM, Glucose 6 mM, and Pyruvate 2 mM) with a combination of growth factor (TGFb at 10 μg/ml) and hormones (Hydrocortisone 500 nM and Dexamethanose 200 nM). The cells are thus in a metastable phenotype, and can be derived in multiple cell types representing different population normally found in mammary gland but also aberrant fibroblast-like cells. An important characteristic of plastic cells is their higher capacity of pliancy, a phenotype associated with their abiliity to support the stress induced by an oncogenic lesion. The inventors thus verified that metastable cells were indeed completely insensitive to an oncogenic stress produced by the genetic activation of a vector encoding a constitutive active form of the protein Ras. At the opposite, all more differentiated cell line derived from this metastable HMECs were not resistant anymore to this oncogene induction (
[0368] Secondly, to show the correlation existing between the level of genetic plasticity and the global membrane fluidity, original HMEC cell line, metastable-derived and redifferentiated cells were incubated 48 h with the DIOLL probe. The generalized polarization (GP) parameter was calculated from emission intensities after excitation at 390 nm according to:
where I.sub.440 and I.sub.490 correspond to measured fluorescence intensities of the whole cells at wavelengths of 440 nm and 490 nm, respectively.
[0369] Highly plastic metastable cells clearly displayed the highest membrane fluidity, while other cell types had lower membrane fluidity (Former HMECs and myoepithelial-like cells presented in the
[0370] Then, an RNAseq was performed to obtain a genetic signature associated with this genetic plasticity and it used to analyse well characterized breast cancer cell lines (
[0371] An intrinsic molecular subtype has been associated to these cell lines through the analyse of their transcriptome and this subtype is associated to several phenotypic features used classically to sort mammary tumours. Her2 subtype present for instance a very strong dependence to this oncogene and are mostly epithelial. Basal-like and Claudin-Low tumour are considered as the most aggressive even if, an important heterogeneity exists between the neoplasia belonging to a same molecular subtype. Claudin-Low, very often presenting the acquisition of new and aberrant mesenchymal differentiated traits, have been recently separated in three different groups, some of them being very less aggressive. At the opposite, basal-like tumours are strongly undifferentiated, hormone independent and more homogeneously aggressive.ln contrast, luminal cell lines show some conservation of their original mammary characteristics such as their ability to respond to hormones, their lower capacity to form tumour and metastasis, and the maintenance in the produced tumour of a glandular shape.
[0372] By using their new transcriptomic signature generated from the metastable cell line, the inventors performed a principal component analysis based on epithelial identity and cell plasticity. As expected, most basal cell line were sorted together in an highly plastic group with a partial lost of their epithelial identity. Interestingly, a much more heterogeneous pattern was observed for Claudin-Low and Luminal-b cell lines with some of them being closer of the basal cell lines. Therefore, this analyse capture the known heterogeneity of Luminal-b and Claudin-Low tumour with a significant part of them being more aggressive and resistant.Then from this characterisation the inventors verified that GP coudl similarly classify these cell lines, this procedure being much more simple to perform than a complete genetic analysis.
[0373] Table 5 below summarizes the different lines studied and their known characteristics.
TABLE-US-00005 TABLE 5 Known Mammary gland tumour cell lines and their specifications Human tumour cell lines Specifications Mammary gland MCF-7 Luminal cell lines responding to ZR-75 hormones, which are very close to epithelial cells BT20 Basal cell lines, dedifferentiated HCC1954 HCC1937 HS578T “Claudin-low” cell lines, aberrant MDA-MB-231 mesenchymal differentiation MDA-MB-436
[0374] One control line were also used, HMEC cells representing normal mammary epithelial luminal progenitors
[0375] The results are summarized in
[0376] It is worth noting that the cells lines were distinguished with DIOLL probe regardless of the temperature at which the I.sub.440 and I.sub.490 were recorded.
[0377] Finally, to complete the previous result, the inventors verified the DIOLL capacity to follow the cell plasticity dynamically in cancerous cell line like in the previous metastable model during its differentiation. HCC1954 was subject during three weeks to a differentiating protocol based on nutritive deprivation and a combination of growth factor (TGFb at 10 μg/ml) and hormones (hydrocortisone 500 nM). The fluidity of their membranes were clearly reduced confirming ability of the DIOLL to measure a dynamic reduction of cell plasticity in a cancerous cell line (
2. Variation of the Membrane Fluidity in Prostate Cell Lines
[0378] Then the inventors verified that the relationship between the degree of genetic plasticity and the fluidity of the membranes was not a particularity of mammary cells but could extend to other neoplasia such as that affecting prostate tissue. 4 cell lines were tested: LNCaP which is a basal cell line, PC-3 which an aggressive metastatic cell line, C4-2B cell line which are mesenchymal cell lines derived from LNCap and WPMY-1 which is an epithelial and mesenchymal control cell line.
[0379] The results are presented in
[0380] It is worth noting here again that the cells lines were distinguished with DIOLL probe regardless of the temperature at which the I.sub.440 and I.sub.490 were recorded.
3. Variation of the Membrane Fluidity in Exosomes
[0381] The analysis of the membranes of exosomes is of twofold interest. Indeed, on one hand, these vesicles are released into the circulation and are therefore easily accessible, making it possible to consider a less invasive diagnostic tool than a tumour biopsy and longitudinal patient follow-up, as the sampling can be repeated several times. On the other hand, the membranes of these vesicles are not subjected to any mechanical stress related to tissue architecture, unlike the cells recovered by biopsy, which eliminates a factor that strongly constrains membrane fluidity and overlaps with the intrinsic properties of these membranes.
1. Exosomes from Differentiated and Dedifferentiated HMEC Cells
[0382] The exosomes from the HMEC cells described above were purified, as described in Example 3, in order to analyse the GP of their membrane. Regardless of the method used, spectrofluorometry (
2. Exosomes from Dedifferentiated HMEC Cells at Different Times of Induction of Dedifferentiation
[0383] Here is studied the kinetic analysis of exosomes from HMEC cells during the lost of their epithelial identity, purified as described in Example 3 (
[0384] The inventors observe that the progressive increase in the fluidity of the membranes of these vesicles is well related to the increase in the level of genetic plasticity of the cells from which they are derived. Therefore, these experiments confirm that the membrane fluidity of exosomes reflects an index of the genetic plasticity of the cells from which their originate.
4. Validation of the Membrane Fluidity in Mouse Tumor
[0385] Finally, inventors verified the ability of membrane fluidity to capture the most plastic cell in an in vivo tumour model. Transgenic mice expressing the c-myc oncogene under a promoter system specifically active in mammary gland and inducible by doxycycline were used and developed epithelial mammary tumour. These tumours can be further made resistant to myc deprivation, acquiring simultaneously a strong plasticity and mesenchymal features. A syngenic model was developed from these tumours recapitulating this course of tumour development in 10 weeks. Importantly, several normal and cancerous populations then co-exist in these tumours, some of them bein characterised as highly plastic from their genetic analysis and a pattern of surface marker (CD29high/CD24high) specifically associated to this model
[0386] These different cell populations from the tumor can be quantified and discriminated by flow cytometry. Of note, when membrane fluidity was analysed simultaneously, highly plastic cells (CD29high/CD24high) had the highest membrane fluidity, whereas normal fibroblasts and erythrocytes presented the strongest rigidity (
Example 7
Labeling of Viral Membranes and Calculation of GP Parameter to Estimate Membrane Fluidity with DIOLL Probe
[0387] 1. Materials and methods
a. Chemicals
[0388] DIOLL probe was synthesis as described in Example 1.
b. Methods
[0389] Viral samples of purified influenza virus (ref Durous et al. Vaccine, 2019) were incubated with 0.2 μM DIOLL under sterile conditions for 1 h. Fluorescence spectra were recorded using a Jasco fluorimeter in quartz sterile cuvettes. Emission spectra were recorded between 410 and 600 nm with an excitation wavelength fixed at 390 nm and 1 nm excitation and emission slits, at 21° C. and 37° C. GP parameter was calculated as described in Example 1.
2. Results
[0390] DIOLL efficiently labeled viral membranes with a maximum fluorescence intensity at 440 nm (